Martin W Britten1, Laura Lümers2, Kenji Tominaga2,3, Jürgen Peters2, Daniel Dirkmann2. 1. Klinik für Anästhesiologie & Intensivmedizin, University of Duisburg-Essen & University Hospital of Essen, Hufelandstr. 55, 45122, Essen, Germany. Martin.Britten@uk-essen.de. 2. Klinik für Anästhesiologie & Intensivmedizin, University of Duisburg-Essen & University Hospital of Essen, Hufelandstr. 55, 45122, Essen, Germany. 3. Present Address: Department of Anesthesiology and Critical Care Medicine, Fukuoka University School of Medicine, Fukuoka, Japan.
Abstract
BACKGROUND: The mechanisms of trauma induced coagulopathy (TIC) are considered multifactorial. Amongst others, however, shedding of the endothelial glycocalyx resulting in increased concentrations of glycocalyx fragments in plasma might also play a role. Thus, we hypothesized that shedded glycocalyx components affect coagulation and may act as humoral mediators of TIC. METHODS: To investigate effects of heparan sulfate, chondroitin sulfate, syndecan-1, versican, and thrombomodulin we added these fragments to in vitro assays of whole blood from healthy volunteers to yield concentrations observed in trauma patients. Platelet function, whole blood coagulation, and fibrinolysis were measured by standard coagulation tests, impedance aggregometry (IA), and viscoelastic tests (VET). To assess dose-response relationships, we performed IA with increasing concentrations of versican and VET with increasing concentrations of thrombomodulin. RESULTS: Intrinsically activated clotting times (i.e., activated partial thromboplastin time and intrinsically activated VET with and without heparinase) were unaffected by any glycocalyx fragment. Thrombomodulin, however, significantly and dose-dependently diminished fibrinolysis as assessed by VET with exogenously added rt-PA, and increased rt-PA-induced lysis Indices after 30 (up to 108% of control, p < 0,0001), 45 (up to 368% of control, p < 0,0001), and 60 min (up to 950% of control, p < 0,0001) in VET. Versican impaired platelet aggregation in response to arachidonic acid (up to - 37,6%, p < 0,0001), ADP (up to - 14,5%, p < 0,0001), and collagen (up to - 31,8%, p < 0,0001) in a dose-dependent manner, but did not affect TRAP-6 induced platelet aggregation. Clotting time in extrinsically activated VET was shortened by heparan sulfate (- 7,2%, p = 0,024), chondroitin sulfate (- 11,6%, p = 0,016), versican (- 13%, p = 0,012%), and when combined (- 7,2%, p = 0,007). CONCLUSIONS: Glycocalyx components exert distinct inhibitory effects on platelet function, coagulation, and fibrinolysis. These data do not support a 'heparin-like auto-anticoagulation' by shed glycosaminoglycans but suggest a possible role of versican in trauma-induced thrombocytopathy and of thrombomodulin in trauma-associated impairment of endogenous fibrinolysis.
BACKGROUND: The mechanisms of trauma induced coagulopathy (TIC) are considered multifactorial. Amongst others, however, shedding of the endothelial glycocalyx resulting in increased concentrations of glycocalyx fragments in plasma might also play a role. Thus, we hypothesized that shedded glycocalyx components affect coagulation and may act as humoral mediators of TIC. METHODS: To investigate effects of heparan sulfate, chondroitin sulfate, syndecan-1, versican, and thrombomodulin we added these fragments to in vitro assays of whole blood from healthy volunteers to yield concentrations observed in trauma patients. Platelet function, whole blood coagulation, and fibrinolysis were measured by standard coagulation tests, impedance aggregometry (IA), and viscoelastic tests (VET). To assess dose-response relationships, we performed IA with increasing concentrations of versican and VET with increasing concentrations of thrombomodulin. RESULTS: Intrinsically activated clotting times (i.e., activated partial thromboplastin time and intrinsically activated VET with and without heparinase) were unaffected by any glycocalyx fragment. Thrombomodulin, however, significantly and dose-dependently diminished fibrinolysis as assessed by VET with exogenously added rt-PA, and increased rt-PA-induced lysis Indices after 30 (up to 108% of control, p < 0,0001), 45 (up to 368% of control, p < 0,0001), and 60 min (up to 950% of control, p < 0,0001) in VET. Versican impaired platelet aggregation in response to arachidonic acid (up to - 37,6%, p < 0,0001), ADP (up to - 14,5%, p < 0,0001), and collagen (up to - 31,8%, p < 0,0001) in a dose-dependent manner, but did not affect TRAP-6 induced platelet aggregation. Clotting time in extrinsically activated VET was shortened by heparan sulfate (- 7,2%, p = 0,024), chondroitin sulfate (- 11,6%, p = 0,016), versican (- 13%, p = 0,012%), and when combined (- 7,2%, p = 0,007). CONCLUSIONS: Glycocalyx components exert distinct inhibitory effects on platelet function, coagulation, and fibrinolysis. These data do not support a 'heparin-like auto-anticoagulation' by shed glycosaminoglycans but suggest a possible role of versican in trauma-induced thrombocytopathy and of thrombomodulin in trauma-associated impairment of endogenous fibrinolysis.
Authors: Sisse R Ostrowski; Hanne H Henriksen; Jakob Stensballe; Mikkel Gybel-Brask; Jessica C Cardenas; Lisa A Baer; Bryan A Cotton; John B Holcomb; Charles E Wade; Pär I Johansson Journal: J Trauma Acute Care Surg Date: 2017-02 Impact factor: 3.313
Authors: Daniel Dirkmann; Martin W Britten; Henning Pauling; Juliane Weidle; Lothar Volbracht; Klaus Görlinger; Jürgen Peters Journal: Anesthesiology Date: 2016-06 Impact factor: 7.892
Authors: Matthew E Kutcher; Brittney J Redick; Ryan C McCreery; Ian M Crane; Molly D Greenberg; Leslie M Cachola; Mary F Nelson; Mitchell Jay Cohen Journal: J Trauma Acute Care Surg Date: 2012-07 Impact factor: 3.313
Authors: B Bode-Lesniewska; M T Dours-Zimmermann; B F Odermatt; J Briner; P U Heitz; D R Zimmermann Journal: J Histochem Cytochem Date: 1996-04 Impact factor: 2.479
Authors: Hunter B Moore; Ernest E Moore; Benjamin R Huebner; Monika Dzieciatkowska; Gregory R Stettler; Geoffrey R Nunns; Peter J Lawson; Arsen Ghasabyan; James Chandler; Anirban Banerjee; Christopher Silliman; Angela Sauaia; Kirk C Hansen Journal: J Trauma Acute Care Surg Date: 2017-12 Impact factor: 3.313
Authors: M Senzolo; J Coppell; E Cholongitas; A Riddell; C K Triantos; D Perry; A K Burroughs Journal: Blood Coagul Fibrinolysis Date: 2007-04 Impact factor: 1.276
Authors: Elaheh Rahbar; Jessica C Cardenas; Gyulnar Baimukanova; Benjamin Usadi; Roberta Bruhn; Shibani Pati; Sisse R Ostrowski; Pär I Johansson; John B Holcomb; Charles E Wade Journal: J Transl Med Date: 2015-04-12 Impact factor: 5.531
Authors: Thomas N Wight; Inkyung Kang; Stephen P Evanko; Ingrid A Harten; Mary Y Chang; Oliver M T Pearce; Carys E Allen; Charles W Frevert Journal: Front Immunol Date: 2020-03-24 Impact factor: 7.561